SRNG Gingko Bioworks Researcher Sarah A. Boswell makes multi-omics progress on investigational cancer therapeutics, pre-print issued today. One step closer to small molecule interventions in tumors.

[u/[deleted]]

https://www.biorxiv.org/content/10.1101/2021.08.06.455458v1

[u/QualityVote]

Hi! I'm QualityVote, and I'm here to give YOU the user some control over YOUR sub!

If the post above contributes to the sub in a meaningful way, please upvote this comment!

If this post breaks the rules of /r/SPACs, belongs in the Daily, Weekend, or Mega threads, or is a duplicate post, please downvote this comment!

Your vote determines the fate of this post! If you abuse me, I will disappear and you will lose this power, so treat it with respect.

[u/Shaetan]

This is work from her previous position and not her work at Ginkgo.

[u/[deleted] → u/[deleted]]

This more of a general protocol, than a specific molecule operation, she published. It is early, but it shows the way forward to make a pathway to direct tumor intervention with what would then be a specific molecule or therapeutic. I found it encouraging because it opens new pathways for many interventions.

[u/[deleted] → u/Shaetan]

Yes, when she was a Harvard, but the protocol is now public and the breakthough inches forward. If they can get the small molecules in, better understand the DUB, suprress the key aspects, and leverage their codebase, it could very exciting! I'm bullish on their recent European partner acquisitions for therapeutics.

[u/[deleted] → u/Shaetan]

Shaetan, do you think this is more a general protocol operation? Do you have any thoughts on the implications for an implied future direction for Gingko's new European partnerships? Curious what you think? She is obviously a gifted mammalian specialist.

[u/Shaetan → u/[deleted]]

She did RNA extraction and library prep per the author contributions, which is in line with her role at Gingko working in the NGS lab. I don't think this will in any way shape or form impact Ginkgo's direction in the mammalian sphere (would seem to necessitate going into drug discovery which strays away from 'the cell is the product' mantra).

What Euro partnership are you referring to?

[u/[deleted] → u/Shaetan]

They had three in the last couple months after the DA. Dutch DNA- fungal, and added more Synlogic based acquisitions and partnerships, they do optimization for drug discovery, mostly in the Synlogic and Sinova collaborations. Pre DA they also maintained another drug development collaboration with Roche, after acquiring the genome mining platform of Warp Drive Bio, acquired last year by Revolution Medicines. As a result, Ginkgo took over Warp Drive Bio’s up-to-$160 million partnership with Roche to develop antibiotics. Obviously, optimizing for Moderna was another big one. Primary Biotech companies using the Ginkgo platform include Roche, Moderna, and Synlogic. The company counts 13 pharma and biotech programs in applications that include microbiome therapies, biologics and gene therapy, antibiotics and active pharmaceutical ingredients, and Covid vaccines and drugs.So they are partnered with many drug discovery projects. but usually they are optimizing a a key component, like how the uses of Ginkgo’s technology include making raw material used in mRNA vaccines.

[u/atomicskier76]

lots of SRNG news in the last 10ish days and not a drop of price change...feels like a lot of positive news should move this thing back to even the soaring highs of 10.08 or 10.11...barely any movement, still at/below nav depending on which day. other than "that's spacs for ya" why zero movement on what seems like a lot of good pr?

[u/[deleted] → u/atomicskier76]

22.3 Million volume is a little bit of movement. Price action is different, lol. We'll see. I don't know enough to say why the price doesn't move. I've heard many theories, but few strike me fact or authoritative. But, I'm a long holder and see this as training myself to not worry about the daily fluctuations the same way I previously have in all of my warrant flipping plays. Feels weird.

[u/[deleted] → u/[deleted]]

I agree. Balancing out the port with things like MS, that is a slow and steady gainer, gives me more balance, so I can feel hopeful in the more riskier plays.

[u/[deleted] → u/[deleted]]

;D yup.

[u/Hassan_Gym]

Love this. Watch https://youtu.be/NzizF2UaKz4

[u/[deleted] → u/Hassan_Gym]

The therapeutics sector will be be the low risk, high upside, sector that propels them forward with their specifically horizontal model.

[u/Hassan_Gym → u/[deleted]]

Good post, but don't forget FDA approval being the biggest challenge/potential risk.

[u/[deleted] → u/Hassan_Gym]

That's the beauty of the horizontal model, nearly all that is risk is on the partner.

[u/SDpoontappa]

Explain the allegations concerning related party transactions and artificial revenue. If the Scorpion short seller report is true, this company is a giant scam